A recent retrospective study published in the Journal of Current Glaucoma Practice in September 2026 reveals that combining cataract surgery with microinvasive glaucoma surgery achieves surgical success in up to 72.4% of eyes. This dual procedure significantly reduces daily drop reliance while lowering net intraocular pressure by up to 3.3 mm Hg.

While topical intraocular pressure–lowering medications represent traditional first-line therapy for primary open-angle glaucoma (POAG), poor adherence—as low as 20% due to cost and drop burden—accelerates visual field loss, prompting MIGS procedures like 360-degree gonioscopy-assisted transluminal trabeculotomy (GATT) and sectoral Kahook Dual Blade (KDB) goniotomy. Addressing conflicting research regarding whether circumferential trabeculotomy provides superior pressure control over sectoral excision, Dr. Dana Shannon and colleagues from the University of Chicago Medicine evaluated 6-month outcomes of phacoemulsification (phaco) combined with GATT versus KDB in a predominantly African American cohort.

Therefore, the 6-month retrospective study evaluated 87 eyes from 61 primary open-angle glaucoma patients undergoing phacoemulsification combined with either 360-degree gonioscopy-assisted transluminal trabeculotomy or Kahook Dual Blade goniotomy. Primary endpoints assessed surgical success—defined as a ≥20% intraocular pressure reduction or ≥1 medication reduction without reoperation—alongside secondary measures of target pressure control, drop independence, and safety.

Key clinical findings from the study include:

  • Equivalent Surgical Success: The study demonstrated comparable 6-month success rates between phaco-GATT (72.4%) and phaco-KDB (60.3%) without statistical difference (p = 0.524).
  • Greater Pressure Lowering: The investigation observed significantly larger net IOP lowering with phaco-GATT than phaco-KDB (3.3 vs. 1.2 mm Hg, p = 0.009), with 51.7% vs. 27.6% reaching ≥20% reduction (p = 0.048).
  • Meaningful Drop Relief: The research revealed significant medication reductions for phaco-GATT (3.2 to 2.6 drops, p = 0.002) and phaco-KDB (2.6 to 2.1 drops, p < 0.001), with 42.5% dropping ≥1 drop and 18.4% achieving drop independence.
  • Postoperative Hyphema Profile: The analysis reported transient hyphema as the main complication, occurring significantly more in phaco-GATT (44.8%) than phaco-KDB (18.9%, p = 0.022).
  • Low Baseline Pressure Utility: The evaluation confirmed that in eyes with baseline IOP ≤15 mm Hg (64.4% of cohort), both procedures effectively reduced medication burden (48.2% reduced ≥1 drop) with equal efficacy (p = 0.445).

The results suggest that both phaco-GATT and phaco-KDB deliver similar 6-month surgical success (72.4% vs. 60.3%) and significant medication burden reduction (42.5% eliminating ≥1 medication) in primary open-angle glaucoma. Although 360-degree trabeculotomy produces greater net IOP lowering (3.3 vs. 1.2 mm Hg), it carries higher transient hyphema rates (44.8% vs. 18.9%), allowing surgeons to tailor procedure selection to patient risk profiles.

Thus, the study concludes clinicians can consider both 360-degree trabeculotomy and sectoral goniotomy as effective adjunctive options during cataract surgery, selecting the appropriate procedure based on individual glaucoma severity, target pressure goals, medication burden, and relative surgical risks.

Although constrained by its retrospective design, potential selection bias toward trabeculotomy in severe cases, and a 6-month follow-up timeline, this study underscores the necessity for prospective, long-term comparative trials across diverse populations to further refine clinical decision-making.

Reference

Shannon D, Qiu M, Gilbertson J, Parekh Z, Khabaz K, Amin P. Comparison of Outcomes at 6 Months between Sectoral Goniotomy and Gonioscopy-assisted Transluminal Trabeculotomy Combined with Cataract Surgery in Primary Open-angle Glaucoma. Journal of Current Glaucoma Practice. 2026;20(3):135–142.



Tags:    
Article Source : Journal of Current Glaucoma Practice

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .